ZOLPIDEM IS AN EFFECTIVE OPTION WITH A REDUCED RISK FOR DEPENDENCE IN THE TREATMENT OF INSOMNIA
Insomnia is a highly prevalent sleep disorder that frequently occurs in its acute form and occurs at a rate of approximately 10 per cent in its chronic form in many countries. There is a high prevalence of insomnia in a variety of medical and psychiatric conditions for which insomnia often serves as a risk factor. There are various types of insomnia which are categorized in terms of how it affects sleep it has been shown to negatively affect many physiological, cognitive, and behavioural measures within the body. Recent years have observed that there is sudden increase of various diseases like hypertension, Heart attack, Obesity, Diabetes etc which occurs as a result of insomnia. Hence its impact on financial, social and psychological status of patients and their caregivers cannot be ignored. Thus finding a novel way to tackle these health problems is the need of present times. The most commonly prescribed medications for insomnia are the benzodiazepines (BZP) such as temazepam and diazepam. Although these medications are efficacious, they are associated with tolerance, dependence, residual daytime sedative effects, cognitive and psychomotor impairment, and discontinuation syndromes including rebound insomnia and withdrawal symptoms. For this reason, BZD use should be judicious and is replaced by Zolpidem, a novel non-benzodiazepine hypnotics of Imidazopyridine class that has various advantages over benzodiazepines. Chronic administration of zolpidem produces neither tolerance to its sedative effects nor signs of withdrawal when the drug is discontinued. Also it has little effect on the stages of sleep in normal human subjects. The drug is as effective as benzodiazepines in shortening sleep latency and prolonging total sleep time in patients with insomnia. Tolerance and physical dependence develop only rarely and under unusual circumstances.
Keywords: Insomnia, sleep disorder, benzodiazepines, tolerance, dependence, zolpidem, Imidazopyridine
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).